Key result
Central boost radiation therapy was described as a treatment approach for an unresectable retroperitoneal sarcoma in this case report.
Case Report
Case report describing the use of central boost radiation therapy for an unresectable retroperitoneal sarcoma.
This is the authors' abstract. We don't add key points for this paper.
Retroperitoneal sarcomas (RPS) comprise 10% to 15% of soft tissue sarcomas and grow to a median of 15 to 18 cm before causing symptomatic invasion or mass effect on surrounding structures.1 Curative treatment for nonmetastatic RPS requires surgical resection, with 65% to 83% undergoing complete resection, while others may be unresectable owing to the tumor invading major vessels or the spinal cord.1-5 In an early series of 278 patients with primary RPS, unresectability was the strongest prognostic factor for disease-specific survival on multivariate analysis (relative risk, 4.7; 95% confidence interval, 2.9-7.5; P = .001), followed by positive margins, high-grade, and size >10 cm.
Answers are grounded in this paper and cite their sources.
May warrant consideration in select unresectable retroperitoneal sarcomas; leaves open prospective validation.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2020) conducted a case report in Unresectable Retroperitoneal Sarcoma. Central Boost Radiation Therapy was evaluated. Central boost radiation therapy was described as a treatment approach for an unresectable retroperitoneal sarcoma in this case report.
Synapse has enriched 10 related papers. Consider them for comparative context: